0001528172
false
--12-31
2021
Q3
0001528172
2021-01-01
2021-09-30
0001528172
2021-11-19
0001528172
2021-09-30
0001528172
2020-12-31
0001528172
ENDV:SuperAASuperVotingPreferredStockMember
2021-09-30
0001528172
ENDV:SuperAASuperVotingPreferredStockMember
2020-12-31
0001528172
ENDV:SeriesBConvertiblePreferredStockMember
2021-09-30
0001528172
ENDV:SeriesBConvertiblePreferredStockMember
2020-12-31
0001528172
ENDV:SeriesCConvertiblePreferredStockMember
2021-09-30
0001528172
ENDV:SeriesCConvertiblePreferredStockMember
2020-12-31
0001528172
ENDV:SeriesDConvertiblePreferredStockMember
2021-09-30
0001528172
ENDV:SeriesDConvertiblePreferredStockMember
2020-12-31
0001528172
2021-07-01
2021-09-30
0001528172
2020-07-01
2020-09-30
0001528172
2020-01-01
2020-09-30
0001528172
2019-12-31
0001528172
2020-09-30
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2019-12-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2019-12-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2019-12-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2019-12-31
0001528172
us-gaap:CommonStockMember
2019-12-31
0001528172
us-gaap:AdditionalPaidInCapitalMember
2019-12-31
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2019-12-31
0001528172
us-gaap:RetainedEarningsMember
2019-12-31
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2020-01-01
2020-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2020-01-01
2020-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2020-01-01
2020-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2020-01-01
2020-03-31
0001528172
us-gaap:CommonStockMember
2020-01-01
2020-03-31
0001528172
us-gaap:AdditionalPaidInCapitalMember
2020-01-01
2020-03-31
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2020-01-01
2020-03-31
0001528172
us-gaap:RetainedEarningsMember
2020-01-01
2020-03-31
0001528172
2020-01-01
2020-03-31
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2020-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2020-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2020-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2020-03-31
0001528172
us-gaap:CommonStockMember
2020-03-31
0001528172
us-gaap:AdditionalPaidInCapitalMember
2020-03-31
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2020-03-31
0001528172
us-gaap:RetainedEarningsMember
2020-03-31
0001528172
2020-03-31
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2020-04-01
2020-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2020-04-01
2020-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2020-04-01
2020-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2020-04-01
2020-06-30
0001528172
us-gaap:CommonStockMember
2020-04-01
2020-06-30
0001528172
us-gaap:AdditionalPaidInCapitalMember
2020-04-01
2020-06-30
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2020-04-01
2020-06-30
0001528172
us-gaap:RetainedEarningsMember
2020-04-01
2020-06-30
0001528172
2020-04-01
2020-06-30
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2020-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2020-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2020-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2020-06-30
0001528172
us-gaap:CommonStockMember
2020-06-30
0001528172
us-gaap:AdditionalPaidInCapitalMember
2020-06-30
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2020-06-30
0001528172
us-gaap:RetainedEarningsMember
2020-06-30
0001528172
2020-06-30
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2020-07-01
2020-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2020-07-01
2020-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2020-07-01
2020-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2020-07-01
2020-09-30
0001528172
us-gaap:CommonStockMember
2020-07-01
2020-09-30
0001528172
us-gaap:AdditionalPaidInCapitalMember
2020-07-01
2020-09-30
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2020-07-01
2020-09-30
0001528172
us-gaap:RetainedEarningsMember
2020-07-01
2020-09-30
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2020-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2020-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2020-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2020-09-30
0001528172
us-gaap:CommonStockMember
2020-09-30
0001528172
us-gaap:AdditionalPaidInCapitalMember
2020-09-30
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2020-09-30
0001528172
us-gaap:RetainedEarningsMember
2020-09-30
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2020-12-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2020-12-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2020-12-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2020-12-31
0001528172
us-gaap:CommonStockMember
2020-12-31
0001528172
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2020-12-31
0001528172
us-gaap:RetainedEarningsMember
2020-12-31
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2021-01-01
2021-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2021-01-01
2021-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2021-01-01
2021-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2021-01-01
2021-03-31
0001528172
us-gaap:CommonStockMember
2021-01-01
2021-03-31
0001528172
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-03-31
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2021-01-01
2021-03-31
0001528172
us-gaap:RetainedEarningsMember
2021-01-01
2021-03-31
0001528172
2021-01-01
2021-03-31
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2021-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2021-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2021-03-31
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2021-03-31
0001528172
us-gaap:CommonStockMember
2021-03-31
0001528172
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2021-03-31
0001528172
us-gaap:RetainedEarningsMember
2021-03-31
0001528172
2021-03-31
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2021-04-01
2021-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2021-04-01
2021-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2021-04-01
2021-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2021-04-01
2021-06-30
0001528172
us-gaap:CommonStockMember
2021-04-01
2021-06-30
0001528172
us-gaap:AdditionalPaidInCapitalMember
2021-04-01
2021-06-30
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2021-04-01
2021-06-30
0001528172
us-gaap:RetainedEarningsMember
2021-04-01
2021-06-30
0001528172
2021-04-01
2021-06-30
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2021-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2021-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2021-06-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2021-06-30
0001528172
us-gaap:CommonStockMember
2021-06-30
0001528172
us-gaap:AdditionalPaidInCapitalMember
2021-06-30
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2021-06-30
0001528172
us-gaap:RetainedEarningsMember
2021-06-30
0001528172
2021-06-30
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2021-07-01
2021-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2021-07-01
2021-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2021-07-01
2021-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2021-07-01
2021-09-30
0001528172
us-gaap:CommonStockMember
2021-07-01
2021-09-30
0001528172
us-gaap:AdditionalPaidInCapitalMember
2021-07-01
2021-09-30
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2021-07-01
2021-09-30
0001528172
us-gaap:RetainedEarningsMember
2021-07-01
2021-09-30
0001528172
ENDV:SeriesAAPreferredStockMember
us-gaap:PreferredStockMember
2021-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesBConvertiblePreferredStockMember
2021-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesCConvertiblePreferredStockMember
2021-09-30
0001528172
us-gaap:PreferredStockMember
ENDV:SeriesDConvertiblePreferredStockMember
2021-09-30
0001528172
us-gaap:CommonStockMember
2021-09-30
0001528172
us-gaap:AdditionalPaidInCapitalMember
2021-09-30
0001528172
ENDV:CommonStockSubscriptionReceivableMember
2021-09-30
0001528172
us-gaap:RetainedEarningsMember
2021-09-30
0001528172
ENDV:DirectSalesMedicalCareProvidersGrossMember
2021-07-01
2021-09-30
0001528172
ENDV:DirectSalesMedicalCareProvidersGrossMember
2020-07-01
2020-09-30
0001528172
ENDV:DirectSalesMedicalCareProvidersGrossMember
2021-01-01
2021-09-30
0001528172
ENDV:DirectSalesMedicalCareProvidersGrossMember
2020-01-01
2020-09-30
0001528172
ENDV:AutosMember
2021-09-30
0001528172
ENDV:AutosMember
2020-12-31
0001528172
ENDV:MedicalEquipmentMember
2021-09-30
0001528172
ENDV:MedicalEquipmentMember
2020-12-31
0001528172
ENDV:OtherEquipmentMember
2021-09-30
0001528172
ENDV:OtherEquipmentMember
2020-12-31
0001528172
ENDV:RioGrandeNeurosciencesIncMember
2017-12-01
2017-12-31
0001528172
ENDV:TwoPromissoryNotesMember
2021-09-30
0001528172
ENDV:TwoPromissoryNotesMember
2021-01-01
2021-09-30
0001528172
us-gaap:GainLossOnDerivativeInstrumentsMember
2021-01-01
2021-09-30
0001528172
ENDV:OnePromissoryNotesMember
2021-01-01
2021-09-30
0001528172
ENDV:PromissoryNotesMember
2021-01-01
2021-09-30
0001528172
ENDV:PromissoryNotesMember
2021-09-30
0001528172
ENDV:ConvertibleDebenturesOneMember
2021-09-30
0001528172
ENDV:ConvertibleDebenturesOneMember
ENDV:PastMaturityMember
2021-09-30
0001528172
ENDV:NotesPayableMember
ENDV:RelatedPartyMember
2021-09-30
0001528172
ENDV:NotesPayableMember
ENDV:RelatedPartyMember
srt:MinimumMember
2021-09-30
0001528172
ENDV:NotesPayableMember
ENDV:RelatedPartyMember
srt:MaximumMember
2021-09-30
0001528172
ENDV:NotesPayableMember
ENDV:RelatedPartyMember
2021-01-01
2021-09-30
0001528172
ENDV:NotesPayableOneMember
2021-09-30
0001528172
ENDV:NotesPayableOneMember
ENDV:PastMaturityMember
2021-09-30
0001528172
2020-01-01
2020-12-31
0001528172
ENDV:FormerRelatedPartyMember
2021-09-30
0001528172
ENDV:NonRelatedPartiesMember
2021-09-30
0001528172
ENDV:PreferredStockDesignatedMember
2021-09-30
0001528172
ENDV:SeriesAAMember
2021-09-30
0001528172
ENDV:PreferredSeriesBMember
2021-09-30
0001528172
ENDV:PreferredSeriesCMember
2021-09-30
0001528172
ENDV:PreferredSeriesDMember
2021-09-30
0001528172
ENDV:UndesignatedMember
2021-09-30
0001528172
ENDV:SeriesAAPreferredStockMember
2013-02-22
0001528172
ENDV:SeriesAAPreferredStockMember
2013-02-21
2013-02-22
0001528172
ENDV:SeriesAAPreferredStockMember
2021-09-30
0001528172
us-gaap:SeriesBPreferredStockMember
2017-02-07
0001528172
us-gaap:SeriesBPreferredStockMember
2017-02-06
2017-02-07
0001528172
us-gaap:SeriesBPreferredStockMember
2021-09-30
0001528172
ENDV:SeriesCConvertibleRedeemablePreferredStockMember
2017-12-22
0001528172
ENDV:SeriesCConvertibleRedeemablePreferredStockMember
2017-12-21
2017-12-22
0001528172
ENDV:SeriesCConvertibleRedeemablePreferredStockMember
2020-01-28
2020-01-29
0001528172
ENDV:SeriesCConvertibleRedeemablePreferredStockMember
2021-09-30
0001528172
ENDV:SeriesCConvertiblePreferredStockMember
2021-01-01
2021-09-30
0001528172
ENDV:SeriesCConvertiblePreferredStockMember
2020-01-01
2020-09-30
0001528172
us-gaap:CommonStockMember
2021-01-01
2021-09-30
0001528172
us-gaap:CommonStockMember
2020-01-01
2020-09-30
0001528172
ENDV:SeriesDConvertiblePreferredStockMember
2019-11-11
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
ENDV:CommitmentSharesMember
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2020-05-16
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
ENDV:CommitmentSharesMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2020-05-16
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
ENDV:CommitmentSharesMember
us-gaap:ShareBasedCompensationAwardTrancheThreeMember
2020-05-16
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
2020-05-16
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
srt:MinimumMember
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
srt:MaximumMember
2020-05-16
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
srt:MaximumMember
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
us-gaap:ShareBasedCompensationAwardTrancheThreeMember
srt:MaximumMember
2020-05-16
2020-05-18
0001528172
ENDV:CavalryFundILPMember
ENDV:EquityLinePurchaseAgreementMember
us-gaap:ShareBasedCompensationAwardTrancheThreeMember
srt:MaximumMember
2020-05-18
0001528172
ENDV:ShareIssuanceForConsiderationMember
2021-01-01
2021-09-30
0001528172
ENDV:ConversionOfSeriesCPreferredStockMember
2021-01-01
2021-09-30
0001528172
ENDV:SettlementOfDebtMember
2021-01-01
2021-09-30
0001528172
ENDV:FormerRelatedPartyMember
2021-01-01
2021-09-30
0001528172
ENDV:CavalryFundILPMember
2020-01-01
2020-09-30
0001528172
ENDV:ConversionOfNotesMember
2020-01-01
2020-09-30
0001528172
ENDV:ConversionOfSeriesCPreferredStockMember
2020-01-01
2020-09-30
0001528172
ENDV:ConversionOfSeriesCStockMember
2020-01-01
2020-09-30
0001528172
ENDV:OneInvestorMember
2020-01-01
2020-09-30
0001528172
ENDV:OneInvestorMember
2020-09-30
0001528172
ENDV:ShareIssuanceForConsiderationMember
2020-01-01
2020-09-30
0001528172
ENDV:StockOptionsMember
2020-01-01
2020-09-30
0001528172
us-gaap:RestrictedStockMember
2020-01-01
2020-09-30
0001528172
ENDV:StockOptionsMember
2020-12-31
0001528172
ENDV:StockOptionsMember
2021-01-01
2021-09-30
0001528172
ENDV:StockOptionsMember
2021-09-30
0001528172
2020-06-10
2020-06-11
0001528172
us-gaap:WarrantMember
2020-12-31
0001528172
us-gaap:WarrantMember
2021-01-01
2021-09-30
0001528172
us-gaap:WarrantMember
2021-09-30
0001528172
srt:ExecutiveOfficerMember
2021-09-30
0001528172
srt:ExecutiveOfficerMember
2021-01-01
2021-09-30
0001528172
ENDV:OneExecutiveOfficerMember
2021-09-30
0001528172
srt:OfficerMember
2021-09-30
0001528172
ENDV:FormerPresidentMember
2021-09-30
0001528172
us-gaap:MeasurementInputExpectedTermMember
srt:MinimumMember
2021-01-01
2021-09-30
0001528172
us-gaap:MeasurementInputExpectedTermMember
srt:MaximumMember
2021-01-01
2021-09-30
0001528172
us-gaap:MeasurementInputExpectedTermMember
srt:MinimumMember
2020-01-01
2020-09-30
0001528172
us-gaap:MeasurementInputExpectedTermMember
srt:MaximumMember
2020-01-01
2020-09-30
0001528172
us-gaap:MeasurementInputExercisePriceMember
srt:MinimumMember
2021-09-30
0001528172
us-gaap:MeasurementInputExercisePriceMember
srt:MaximumMember
2021-09-30
0001528172
us-gaap:MeasurementInputExercisePriceMember
srt:MinimumMember
2020-09-30
0001528172
us-gaap:MeasurementInputExercisePriceMember
srt:MaximumMember
2020-09-30
0001528172
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2021-09-30
0001528172
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2021-09-30
0001528172
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2020-09-30
0001528172
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2020-09-30
0001528172
us-gaap:MeasurementInputExpectedDividendRateMember
2021-09-30
0001528172
us-gaap:MeasurementInputExpectedDividendRateMember
2020-09-30
0001528172
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2021-09-30
0001528172
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2021-09-30
0001528172
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2020-09-30
0001528172
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2020-09-30
0001528172
ENDV:ForfeituresMember
2021-09-30
0001528172
ENDV:ForfeituresMember
2020-09-30
0001528172
us-gaap:FairValueInputsLevel3Member
2020-12-31
0001528172
us-gaap:FairValueInputsLevel3Member
2021-01-01
2021-09-30
0001528172
us-gaap:FairValueInputsLevel3Member
2021-09-30
0001528172
us-gaap:FairValueInputsLevel1Member
2021-09-30
0001528172
us-gaap:FairValueInputsLevel2Member
2021-09-30
0001528172
ENDV:AuctusFundLLCMember
ENDV:NoteMember
2019-08-01
2019-08-31
0001528172
ENDV:AuctusFundLLCMember
ENDV:OtherUnspecifiedDamagesAndAttorneyFeesMember
2019-08-01
2019-08-31
0001528172
us-gaap:ConvertibleDebtMember
ENDV:VariableRateMember
2021-09-30
0001528172
us-gaap:SalesRevenueNetMember
us-gaap:SupplierConcentrationRiskMember
ENDV:TwoSignificantCustomersMember
2021-01-01
2021-09-30
0001528172
us-gaap:SalesRevenueNetMember
us-gaap:SupplierConcentrationRiskMember
ENDV:SupplierMember
2021-01-01
2021-09-30
0001528172
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
ENDV:OneCustomerMember
2021-01-01
2021-09-30
0001528172
us-gaap:RestrictedStockMember
2021-08-01
2021-08-05
0001528172
us-gaap:RestrictedStockMember
2021-08-05
0001528172
ENDV:ConvertibleNotesPayableTwoMember
2021-09-30
0001528172
ENDV:ConvertibleNotesPayableTwoMember
2021-08-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended September 30, 2021.
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from _______ to _______.
Commission
File Number: 000-55453
ENDONOVO
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
45-2552528 |
(State
or other jurisdiction of |
|
(I.R.S.
Employer |
incorporation
or organization) |
|
Identification
No.) |
6320
Canoga Avenue, 15th Floor, Woodland Hills, CA 91367
(Address
of principal executive offices, zip code)
(800)
489-4774
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Securities Exchange Act: None
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes
☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large-accelerated filer,” “accelerated filer,”
“non-accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2
of the Exchange Act.
Large
accelerated filer ☐ |
Accelerated
filer ☐ |
|
|
Non-accelerated
filer ☒ |
Smaller
reporting company ☒ |
|
|
|
Emerging
growth company ☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
☐ No ☒
As
of November 19, 2021, there were 72,013,761
shares of common stock, $0.0001 par value
issued and outstanding.
ENDONOVO
THERAPEUTICS, INC.
TABLE
OF CONTENTS
FORM
10-Q REPORT
September
30, 2021
PART
I - FINANCIAL INFORMATION
Item
1. Financial Statements.
Endonovo
Therapeutics, Inc. and Subsidiaries
Condensed
Consolidated Balance Sheets
| |
September
30, 2021 | | |
December
31, 2020 | |
| |
(Unaudited) | | |
(Audited) | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
Current
assets: | |
| | | |
| | |
Cash | |
$ | 5,732 | | |
$ | 13,420 | |
Accounts
receivable, net of allowance for doubtful accounts of $0 | |
| 7,092 | | |
| 942 | |
Prepaid
expenses and other current assets | |
| 49,725 | | |
| 31,825 | |
Total
current assets | |
| 62,549 | | |
| 46,187 | |
| |
| | | |
| | |
Property,
Plant and Equipment, net | |
| - | | |
| 1,580 | |
Patents,
net | |
| 2,074,084 | | |
| 2,559,268 | |
Total
assets | |
$ | 2,136,633 | | |
$ | 2,607,035 | |
| |
| | | |
| | |
LIABILITIES
AND SHAREHOLDERS’ DEFICIT | |
| | | |
| | |
Current
liabilities | |
| | | |
| | |
Accounts
payable | |
$ | 753,041 | | |
$ | 700,932 | |
Accrued
interest | |
| 2,334,302 | | |
| 1,904,136 | |
Deferred
compensation | |
| 3,970,056 | | |
| 3,384,117 | |
Notes
payable, net of discounts of $48,927 and $201,157 as of September 30, 2021, and December 31, 2020 | |
| 6,639,056 | | |
| 6,491,039 | |
Notes
payable – former related party | |
| 132,600 | | |
| 143,000 | |
Derivative
liability | |
| 6,446,149 | | |
| 4,202,597 | |
| |
| | | |
| | |
Total
current liabilities | |
| 20,275,204 | | |
| 16,825,821 | |
| |
| | | |
| | |
Acquisition
payable | |
| 79,825 | | |
| 155,000 | |
Total
liabilities | |
| 20,355,029 | | |
| 16,980,821 | |
COMMITMENTS
AND CONTINGENCIES, note 10 | |
| - | | |
| | |
| |
| | | |
| | |
Shareholders’
deficit | |
| | | |
| | |
Super
AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 25,000 issued and outstanding at September 30, 2021,
and December 31, 2020 | |
| 25 | | |
| 25 | |
Series
B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 600 shares issued and outstanding at September 30, 2021,
and December 31, 2020 | |
| 1 | | |
| 1 | |
| |
| | | |
| | |
Series
C convertible preferred stock, $0.0001 par value; 8,000 shares authorized, 738 and 763 shares issued and outstanding at September
30, 2021, and December 31, 2020 | |
| - | | |
| - | |
| |
| | | |
| | |
Series
D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 305 issued and outstanding at September 30, 2021, and
December 31, 2020 | |
| - | | |
| - | |
Preferred
value | |
| - | | |
| | |
| |
| | | |
| | |
Common
stock, $0.0001 par value; 2,500,000,000 shares authorized; 69,193,105 and 24,536,689 shares issued and outstanding as of September
30, 2021, and December 31, 2020 | |
| 6,920 | | |
| 2,453 | |
Additional
paid-in capital | |
| 40,615,974 | | |
| 38,963,827 | |
Stock
subscriptions | |
| (1,570 | ) | |
| (1,570 | ) |
Accumulated
deficit | |
| (58,839,746 | ) | |
| (53,338,522 | ) |
Total
shareholders’ deficit | |
| (18,218,396 | ) | |
| (14,373,786 | ) |
Total
liabilities and shareholders’ deficit | |
$ | 2,136,633 | | |
$ | 2,607,035 | |
See
accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.
Endonovo
Therapeutics, Inc. and Subsidiaries
Condensed
Consolidated Statements of Operations
(Unaudited)
| |
| | |
| | |
| | |
| |
| |
Three
Months Ended | | |
Nine
Months Ended | |
| |
September
30, | | |
September
30, | |
| |
2021 | | |
2020 | | |
2021 | | |
2020 | |
| |
| | |
| | |
| | |
| |
Revenue | |
$ | 7,790 | | |
$ | 39,980 | | |
$ | 72,789 | | |
$ | 154,296 | |
Cost of revenue | |
| 3,103 | | |
| 760 | | |
| 6,124 | | |
| 18,320 | |
Gross
profit | |
| 4,687 | | |
| 39,220 | | |
| 66,665 | | |
| 135,976 | |
| |
| | | |
| | | |
| | | |
| | |
Operating
expenses | |
| 696,943 | | |
| 986,019 | | |
| 1,919,418 | | |
| 2,364,213 | |
Loss
from operations | |
| (692,256 | ) | |
| (946,799 | ) | |
| (1,852,753 | ) | |
| (2,228,237 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other
income (expense) | |
| | | |
| | | |
| | | |
| | |
Change
in fair value of derivative liability | |
| (542,346 | ) | |
| 416,370 | | |
| (2,962,795 | ) | |
| 6,016,625 | |
Gain
(loss) on settlement of debt | |
| (42,460 | ) | |
| (47,602 | ) | |
| 28,536 | | |
| (564,385 | ) |
Other
expense | |
| - | | |
| (58,902 | ) | |
| - | | |
| (58,902 | ) |
Interest
expense, net | |
| (246,612 | ) | |
| (432,108 | ) | |
| (714,212 | ) | |
| (1,530,375 | ) |
Other
income (expense) | |
| (831,418 | ) | |
| (122,242 | ) | |
| (3,648,471 | ) | |
| 3,862,963 | |
| |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Provision
for income taxes | |
| - | | |
| - | | |
| - | | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net
Income (loss) income | |
$ | (1,523,674 | ) | |
$ | (1,069,041 | ) | |
$ | (5,501,224 | ) | |
$ | 1,634,726 | |
| |
| | | |
| | | |
| | | |
| | |
Basic Income (Loss)
per share | |
$ | (0.02 | ) | |
$ | (0.07 | ) | |
$ | (0.10 | ) | |
$ | 0.17 | |
Diluted Income (Loss)
per share | |
$ | (0.02 | ) | |
$ | (0.07 | ) | |
$ | (0.10 | ) | |
$ | (0.15 | ) |
Weighted average
common share outstanding: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 66,291,292 | | |
| 16,137,373 | | |
| 55,303,026 | | |
| 9,621,530 | |
Diluted | |
| 66,291,292 | | |
| 16,137,373 | | |
| 55,303,026 | | |
| 23,575,380 | |
See
accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.
Endonovo
Therapeutics, Inc. and Subsidiaries
Condensed
Consolidated Statements of Cash Flows
(Unaudited)
| |
| | |
| |
| |
Nine
Months ended September 30, | |
| |
2021 | | |
2020 | |
Operating
activities: | |
| | | |
| | |
Net
(Loss) Income | |
$ | (5,501,224 | ) | |
$ | 1,634,726 | |
Adjustments
to reconcile net (loss) income to cash used in operating activities: | |
| | | |
| | |
Depreciation
and amortization expense | |
| 486,764 | | |
| 488,616 | |
Stock
compensation expense | |
| 61,453 | | |
| 400,108 | |
Fair
value of commitment shares issued with debt | |
| 70,971 | | |
| - | |
Fair
value of equity issued for services | |
| 95,250 | | |
| 13,067 | |
Loss
(gain) on extinguishment of debt | |
| (28,536 | ) | |
| 564,385 | |
Amortization
of note discount and original issue discount | |
| 103,659 | | |
| 50,348 | |
Amortization
of discount on Series C Preferred stock liability | |
| - | | |
| 248 | |
Non-cash
interest expense | |
| - | | |
| 713,462 | |
Change
in fair value of derivative liability | |
| 2,962,795 | | |
| (6,016,625 | ) |
Changes
in assets and liabilities: | |
| | | |
| | |
Accounts
receivable | |
| (6,150 | ) | |
| 21,800 | |
Deposit | |
| - | | |
| (2,500 | ) |
Prepaid
expenses and other current assets | |
| (17,900 | ) | |
| 18,320 | |
Account
payable | |
| 52,109 | | |
| 82,006 | |
Accrued
interest | |
| 539,582 | | |
| 766,319 | |
Deferred
compensation | |
| 585,939 | | |
| 716,986 | |
Net
cash used in operating activities | |
| (595,288 | ) | |
| (548,734 | ) |
| |
| | | |
| | |
Financing
activities: | |
| | | |
| | |
Proceeds
from the issuance of notes payable | |
| 475,000 | | |
| 401,424 | |
Repayments
to former related-party of notes payable | |
| (10,400 | ) | |
| (19,000 | ) |
Repayments
of convertible debt in cash | |
| (3,000 | ) | |
| - | |
Proceeds
from issuance of common stock and units | |
| 126,000 | | |
| 100,000 | |
Proceeds
from issuance of preferred stock | |
| - | | |
| 50,000 | |
Net
cash provided by financing activities | |
| 587,600 | | |
| 532,424 | |
| |
| | | |
| | |
Net
decrease in cash | |
| (7,688 | ) | |
| (16,310 | ) |
Cash,
beginning of year | |
| 13,420 | | |
| 18,893 | |
Cash,
end of period | |
$ | 5,732 | | |
$ | 2,583 | |
| |
| | | |
| | |
Supplemental
disclosure of cash flow information: | |
| | | |
| | |
Cash
paid for interest | |
$ | - | | |
$ | - | |
Cash
paid for income taxes | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
Non-Cash
Investing and Financing Activities: | |
| | | |
| | |
Conversion
of notes payable and accrued interest to common stock | |
$ | 458,335 | | |
$ | 1,357,573 | |
Issuance of
common stock to settle debt | |
$ | 127,522 | | |
$ | - | |
Conversion
of Preferred C Stock to common stock | |
$ | 33,333 | | |
$ | 1,400,934 | |
Issuance
of common stock to Preferred C Stock inducement | |
$ | - | | |
$ | 8,152 | |
Exchange
of note and accrued interest to new convertible note | |
$ | - | | |
$ | 316,494 | |
See
accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.
Endonovo
Therapeutics, Inc. and Subsidiaries
Condensed
Consolidated Statement of Shareholders’ Deficit
(Unaudited)
For
nine months ended September 30, 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series
AA |
|
|
Series
B Convertible |
|
|
Series
D Convertible |
|
|
Series
C Convertible |
|
|
|
|
|
Additional |
|
|
|
|
|
|
|
|
Total |
|
|
|
Preferred
Stock |
|
|
Preferred
Stock |
|
|
Preferred
Stock |
|
|
Preferred
Stock |
|
|
Common
Stock |
|
|
Paid-in |
|
|
Subscription |
|
|
Retained |
|
|
Shareholder’s |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Receivable |
|
|
Earnings |
|
|
Deficit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
December 31, 2019 |
|
|
25,000 |
|
|
$ |
25 |
|
|
|
600 |
|
|
$ |
1 |
|
|
|
255 |
|
|
$ |
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,189,204 |
|
|
$ |
118 |
|
|
$ |
32,432,392 |
|
|
$ |
(1,570 |
) |
|
$ |
(52,934,786 |
) |
|
$ |
(20,503,820 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reclassification
Preferred Series C |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,814 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,418,269 |
|
|
|
- |
|
|
|
- |
|
|
|
2,418,269 |
|
Shares
issued for Preferred Series D |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
50 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
50,000 |
|
|
|
- |
|
|
|
- |
|
|
|
50,000 |
|
Shares
issued for conversion of notes payable and accrued interest |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
4,388,291 |
|
|
|
439 |
|
|
|
2,545,275 |
|
|
|
- |
|
|
|
- |
|
|
|
2,545,714 |
|
Shares
issued for conversion of Preferred Series C to common share |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(936 |
) |
|
|
- |
|
|
|
1,636,166 |
|
|
|
164 |
|
|
|
(164 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Valuation
of stock options issued for services |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
9,567 |
|
|
|
- |
|
|
|
- |
|
|
|
9,567 |
|
Restricted
shares issued as inducement to Series C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted
shares issued as inducement to Series C, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock issued for services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock issued for services, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitment
shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitment
shares, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock issued with exchange of convertible notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock issued with exchange of convertible notes, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued for exchange of stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued for exchange of stock options, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued as inducement to note holder |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued as inducement to note holder, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued as commitment to note holders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Shares issued for debt settlement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Shares issued for debt settlement, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued as settlement of debt with former related party |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued as settlement of debt with former related party, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
shares issued pursuant to consulting agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
shares issued pursuant to consulting agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
shares issued as commitment to note holders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss for the quarter ended March 31, 2020 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
- |
|
|
|
4,338,418 |
|
|
|
4,338,418 |
|
Balance
March 31, 2020 |
|
|
25,000 |
|
|
|
25 |
|
|
|
600 |
|
|
|
1 |
|
|
|
305 |
|
|
|
- |
|
|
|
878 |
|
|
|
- |
|
|
|
7,213,661 |
|
|
|
721 |
|
|
|
37,455,339 |
|
|
|
(1,570 |
) |
|
|
(48,596,368 |
) |
|
|
(11,141,852 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued for conversion of Preferred Series C to Common share |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(105 |
) |
|
|
- |
|
|
|
985,322 |
|
|
|
99 |
|
|
|
27 |
|
|
|
- |
|
|
|
- |
|
|
|
126 |
|
Shares
issued for conversion of notes payable and accrued interest |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
3,353,044 |
|
|
|
335 |
|
|
|
475,627 |
|
|
|
- |
|
|
|
- |
|
|
|
475,962 |
|
Restricted
shares issued as inducement to Series C |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
58,428 |
|
|
|
6 |
|
|
|
8,146 |
|
|
|
- |
|
|
|
(8,152 |
) |
|
|
- |
|
Common
stock issued for services |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
25,000 |
|
|
|
3 |
|
|
|
3,497 |
|
|
|
- |
|
|
|
- |
|
|
|
3,500 |
|
Commitment
shares |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
385,963 |
|
|
|
39 |
|
|
|
55,501 |
|
|
|
- |
|
|
|
- |
|
|
|
55,540 |
|
Common
stock issued with exchange of convertible notes |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
409,000 |
|
|
|
41 |
|
|
|
58,814 |
|
|
|
- |
|
|
|
- |
|
|
|
58,855 |
|
Net
loss for the quarter ended June 30, 2020 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(1,634,651 |
) |
|
|
(1,634,651 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
June 30, 2020 |
|
|
25,000 |
|
|
|
25 |
|
|
|
600 |
|
|
|
1 |
|
|
|
305 |
|
|
|
- |
|
|
|
773 |
|
|
|
- |
|
|
|
12,430,418 |
|
|
|
1,244 |
|
|
|
38,056,951 |
|
|
|
(1,570 |
) |
|
|
(50,239,171 |
) |
|
|
(12,182,520 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
issued for conversion of Preferred Series C to Common share |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(10 |
) |
|
|
- |
|
|
|
133,334 |
|
|
|
13 |
|
|
|
(13 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Shares
issued for exchange of stock options |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,500,000 |
|
|
|
150 |
|
|
|
164,850 |
|
|
|
- |
|
|
|
- |
|
|
|
165,000 |
|
Shares
issued as inducement to note holder |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
500,000 |
|
|
|
50 |
|
|
|
54,950 |
|
|
|
- |
|
|
|
- |
|
|
|
55,000 |
|
Shares
issued for conversion of notes payable and accrued interest |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
759,669 |
|
|
|
76 |
|
|
|
70,334 |
|
|
|
- |
|
|
|
- |
|
|
|
70,410 |
|
Common
stock issued for cash |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,234,568 |
|
|
|
123 |
|
|
|
99,877 |
|
|
|
- |
|
|
|
- |
|
|
|
100,000 |
|
Common
stock issued for services |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
360,000 |
|
|
|
36 |
|
|
|
35,964 |
|
|
|
- |
|
|
|
- |
|
|
|
36,000 |
|
Valuation
of stock options issued for services |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
20,490 |
|
|
|
- |
|
|
|
- |
|
|
|
20,490 |
|
Commitment
shares |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
385,963 |
|
|
|
39 |
|
|
|
42,340 |
|
|
|
- |
|
|
|
- |
|
|
|
42,379 |
|
Net
loss for the quarter ended September 30, 2020 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(1,069,041 |
) |
|
|
(1,069,041 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
September 30, 2020 |
|
|
25,000 |
|
|
|
25 |
|
|
|
600 |
|
|
|
1 |
|
|
|
305 |
|
|
|
- |
|
|
|
763 |
|
|
|
- |
|
|
|
17,303,952 |
|
|
|
1,731 |
|
|
|
38,545,743 |
|
|
|
(1,570 |
) |
|
|
(51,308,212 |
) |
|
|
(12,762,282 |
) |
For
nine months ended September 30, 2021.
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Receivable |
|
|
Earnings |
|
|
Deficit |
|
|
|
Series
AA |
|
|
Series
B Convertible |
|
|
Series
C Convertible |
|
|
Series
D Convertible |
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
|
|
Total |
|
|
|
Preferred
Stock |
|
|
Preferred
Stock |
|
|
Preferred
Stock |
|
|
Preferred
Stock |
|
|
Common
Stock |
|
|
Paid-in |
|
|
Subscription |
|
|
Retained |
|
|
Shareholder’s |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Receivable |
|
|
Earnings |
|
|
Deficit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
December 31, 2020 |
|
|
25,000 |
|
|
$ |
25 |
|
|
|
600 |
|
|
$ |
1 |
|
|
|
|